| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cardiovascular toxicity of breast cancer treatment: an update
|
Papageorgiou, Christos
|
|
|
88 |
1 |
p. 15-24
|
artikel
|
| 2 |
Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors
|
Pastvova, N.
|
|
|
88 |
1 |
p. 89-98
|
artikel
|
| 3 |
Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
|
Yamashita‑Kashima, Yoriko
|
|
|
88 |
1 |
p. 169
|
artikel
|
| 4 |
Correction to: Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance
|
White-Koning, Melanie
|
|
|
88 |
1 |
p. 171
|
artikel
|
| 5 |
Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report
|
Boerrigter, Emmy
|
|
|
88 |
1 |
p. 165-168
|
artikel
|
| 6 |
Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia
|
Larsen, Rikke Hebo
|
|
|
88 |
1 |
p. 53-60
|
artikel
|
| 7 |
Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy
|
A. Mahrous, Mohamed
|
|
|
88 |
1 |
p. 121-129
|
artikel
|
| 8 |
Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma
|
Mori, Shozo
|
|
|
88 |
1 |
p. 109-120
|
artikel
|
| 9 |
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
|
Saad, Fred
|
|
|
88 |
1 |
p. 25-37
|
artikel
|
| 10 |
Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
|
Sugisawa, Norihiko
|
|
|
88 |
1 |
p. 61-67
|
artikel
|
| 11 |
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study
|
Michael, Michael
|
|
|
88 |
1 |
p. 39-52
|
artikel
|
| 12 |
Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women
|
Xu, Binghe
|
|
|
88 |
1 |
p. 131-141
|
artikel
|
| 13 |
Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors
|
Nitani, Chika
|
|
|
88 |
1 |
p. 99-107
|
artikel
|
| 14 |
Selinexor population pharmacokinetic and exposure–response analyses to support dose optimization in patients with diffuse large B-cell lymphoma
|
Xu, Hongmei
|
|
|
88 |
1 |
p. 69-79
|
artikel
|
| 15 |
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma
|
Cheng, Chiung-Chi
|
|
|
88 |
1 |
p. 143-153
|
artikel
|
| 16 |
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
|
Mu, Song
|
|
|
88 |
1 |
p. 81-88
|
artikel
|
| 17 |
Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib
|
Wang, Nianxue
|
|
|
88 |
1 |
p. 155-164
|
artikel
|
| 18 |
Use of cucurbitacins for lung cancer research and therapy
|
Liu, Min
|
|
|
88 |
1 |
p. 1-14
|
artikel
|
Tijdschrift beschrijving